Antifungal

(redirected from Antifungal drug)
Also found in: Dictionary, Thesaurus, Medical, Wikipedia.

Antifungal

 

a medicinal preparation used to treat such fungal diseases as dermatomycoses, onychomycoses, and candidiasis. Externally, antifungals are applied locally to the focus of the infection in the form of ointments, solutions, and other medicines. They are used to remove skin epidermis, hair, and nails infected by a fungus (salicylic and lactic acid preparations). Other antifungals suppress fungal growth (Amicazol [Asterol Dihydrochloride], Zincundan, and Nitrofungin). Systemic antifungals either kill fungi or inhibit their reproduction when taken orally (griseofulvin, nystatin, Levorin) or when injected intravenously (amphotericin B).

References in periodicals archive ?
Resistance without Prior Exposure to Antifungal Drugs
To enhance the efficacy of antifungal drugs, their combined use with the EOs is one of the promising strategies (Giordani et al.
The company's initial priorities are the development of biofilm inhibitors, antifungal drugs, and a portfolio of technologies to enhance the production of microbially produced drugs and other metabolites.
Current Market Situations of China's Major Antifungal Drug Varieties
Some of the restraints to market's growth are growing resistance to antifungal drugs, limitations with antifungal drugs, presence of generics and government regulations in pharmaceutical industry.
The researchers say that their findings attain significance because only one new class of antifungal drugs has been introduced in the last two decades, and they must be administered intravenously.
Antifungal drug susceptibility testing of clinical isolates demonstrated relatively high MICs to all antifungal drugs tested (Table 2).
Antifungal drug resistance is quickly becoming a major problem in the expanding population of immunocompromised persons.
Although CAI (carboxamide-amino-imidazole) was originally developed as an antifungal drug by the Merck Institute for Therapeutic Research, Liotta's team discovered that it also trips up traveling tumor cells.
The product is designed to target the site of infection directly with a novel formulation of amphotericin B, a broad spectrum, "gold-standard" antifungal drug.
The new FDA approved antifungal drug product is the 6th approved antibacterial or antifungal medicine designated as a Qualified Infectious Disease Product (QIDP).
Antifungal drug susceptibilities of oral Candida dubliniensis isolates from human immunodeficiency virus (HIV)-infected and non-HIV-infected subjects and generation of stable fluconazole-resistant derivatives in vitro.